Neoadjuvant chemotherapy in breast cancer of consensuses and controversial perspectives
10.3760/cma.j.cn112152-20190214-00086
- VernacularTitle:乳腺癌新辅助化疗的共识与争议
- Author:
Hai WANG
1
;
Sheng CHEN
;
Junjie LI
;
Zhimin SHAO
Author Information
1. 复旦大学附属肿瘤医院乳腺外科 复旦大学上海医学院肿瘤学系 200032
- Keywords:
Breast neoplasms;
Neoadjuvant chemotherapy;
Indication;
Treatment strategy
- From:
Chinese Journal of Oncology
2021;43(4):504-509
- CountryChina
- Language:Chinese
-
Abstract:
Neoadjuvant chemotherapy (NACT) is a vital part of the systemic treatment to breast cancer. With the formation of consensuses on NACT, controversial perspectives on NACT have been widely discussed, especially in the fields of indication and therapeutic strategy. To define the indication of NACT, blind obedience to the results of clinical trials is not recommended. Instead, indications of NACT should be strictly controlled based on the targets of the clinical practice. Oriented by the early effectiveness of NACT, various chemotherapy or local therapeutics for different molecular subtypes of breast cancer should be conducted to the patients with unsatisfied effect. What′s more, the evolvement of precision medicine accelerates the research of drugs and helps to form an individualized NACT plan. After clarifying the controversial opinions towards NACT in breast cancer, controlling the indication and optimizing the therapeutic strategy will improve the survival of breast cancer patients.
